PVLA
Palvella·NASDAQ
--
--(--)
--
--(--)
PVLA fundamentals
Palvella (PVLA) expects to report earnings on Mar 31, 2026, with estimated revenue of 0 (YoY --), and EPS at -0.9112 (YoY --).
Revenue estimate / YoY
0
--
EPS estimate / YoY
-0.9112
--
Report date
Mar 31, 2026
PVLA Earnings Call Summary for Q4,2025
- Breakthrough Pipeline Momentum: Phase II CVM data exceed expectations, Phase III SELVA study enrollment surpasses targets, and $230M financing secures 2027 FDA approval path.
- Commercial Readiness: 20-40 sales rep hiring, patient services hub, and $100K-$200K pricing for MLM launch.
- Financial Strength: $274M cash runway supports all programs, with 2026 cash burn of ~$80M.
- FDA Alignment: Single-arm Phase III design for MLM validated, 98% patient retention in Phase III SELVA study.
- Pipeline Expansion: QTORIN platform expands to 6 diseases, with Phase II DSAP and angiokeratoma studies in 2026.
EPS
Actual | -5.6 | -7.2 | -20.8 | -20.8 | -5.6 | -20 | -19.2 | -12 | -5.6 | -11.2 | -10.4 | -8.8 | -14.4 | -1.18 | -0.74 | -0.86 | -1.03 | ||||||||||||||||
Forecast | -13.28 | -13.76 | -10.4 | -18.9333 | -13.6 | -17.6 | -19.4667 | -10.8 | -9.2 | -8.8 | -12.8 | -18.36 | -14.676 | -8.8 | -9.6 | -4.8 | -2.4 | -4 | -1.2113 | -0.7409 | -0.8383 | -0.9112 | |||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +57.83% | +47.67% | -100.00% | -9.86% | +58.82% | -13.64% | +1.37% | -11.11% | +39.13% | -27.27% | +18.75% | +52.07% | +1.88% | 0.00% | 0.00% | 0.00% | 0.00% | +70.50% | 0.00% | +38.91% | -16.08% | -22.87% | 0.00% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 13.26M | 11.25M | 2.94M | 1.88M | 15.63M | 3.29M | 4.06M | 8.44M | 10.99M | 3.70M | 5.37M | 5.84M | 1.94M | -- | -- | -- | -- | 0 | -- | 0 | 0 | 0 | -- |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.95M | 8.03M | 11.72M | 3.82M | 6.47M | 5.67M | 5.32M | 8.20M | 11.30M | 10.47M | 4.51M | 6.51M | 2.72M | 7.74M | 2.24M | 2.24M | 2.24M | 1.07M | -- | 0 | 0 | 0 | 0 |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +48.17% | +40.14% | -74.92% | -50.78% | +141.75% | -42.10% | -23.70% | +2.90% | -2.80% | -64.68% | +19.05% | -10.27% | -28.77% | 0.00% | 0.00% | 0.00% | 0.00% | -100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings Call
You can ask Aime
What were the key takeaways from Palvella’s earnings call?What guidance did Palvella's management provide for the next earnings period?What is Palvella's gross profit margin?What is the revenue and EPS growth rate for Palvella year over year?What were the key takeaways from Palvella's earnings call?What is Palvella's latest dividend and current dividend yield?What factors drove the changes in Palvella's revenue and profit?What does Palvella do and what are its main business segments?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
